Trump Administration Declines USMCA Renewal, Opens Talks on New Trade Changes 
Asian Stocks Slide as Chip Shares Tumble Ahead of Key U.S. Jobs Report 
Moody’s Says Peru’s President-Elect Keiko Fujimori Could Boost Investor Confidence 
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Australia Trade Balance Swings to Surprise Deficit as Imports Outpace Exports in May 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Denmark Central Bank Intervenes to Support Krone Peg Against Euro 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
US Stock Futures Hold Steady Ahead of June Jobs Report as Fed Rate Outlook Remains in Focus 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Japan Signals Readiness to Act on Yen as Intervention Speculation Grows 
Gold Price Surges Above $4,120 as Weak US Jobs Data Lowers Fed Rate Hike Expectations 
JPMorgan Cuts Gold Price Forecast, Sees Bullion Reaching $4,500 by End of 2026 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
